Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Dewan, P, Docherty, KF, Bengtsson, O, de Boer, RA, Desai, AS, Drozdz, J, Hawkins, NM, Inzucchi, SE, Kitakaze, M, Køber, L, Kosiborod, MN, Langkilde, AM, Lindholm, D, Martinez, FA, Merkely, B, Petrie, MC, Ponikowski, P, Sabatine, MS, Schou, M, Sjöstrand, M, Solomon, SD, Verma, S, Jhund, PS & McMurray, JJV 2021, 'Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF', European Journal of Heart Failure, vol. 23, no. 4, pp. 632-643. https://doi.org/10.1002/ejhf.2083

APA

Dewan, P., Docherty, K. F., Bengtsson, O., de Boer, R. A., Desai, A. S., Drozdz, J., Hawkins, N. M., Inzucchi, S. E., Kitakaze, M., Køber, L., Kosiborod, M. N., Langkilde, A. M., Lindholm, D., Martinez, F. A., Merkely, B., Petrie, M. C., Ponikowski, P., Sabatine, M. S., Schou, M., ... McMurray, J. J. V. (2021). Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), 632-643. https://doi.org/10.1002/ejhf.2083

CBE

Dewan P, Docherty KF, Bengtsson O, de Boer RA, Desai AS, Drozdz J, Hawkins NM, Inzucchi SE, Kitakaze M, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Verma S, Jhund PS, McMurray JJV. 2021. Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure. 23(4):632-643. https://doi.org/10.1002/ejhf.2083

MLA

Vancouver

Author

Dewan, Pooja ; Docherty, Kieran F ; Bengtsson, Olof ; de Boer, Rudolf A ; Desai, Akshay S ; Drozdz, Jaroslaw ; Hawkins, Nathaniel M ; Inzucchi, Silvio E ; Kitakaze, Masafumi ; Køber, Lars ; Kosiborod, Mikail N ; Langkilde, Anna Maria ; Lindholm, Daniel ; Martinez, Felipe A ; Merkely, Béla ; Petrie, Mark C ; Ponikowski, Piotr ; Sabatine, Marc S ; Schou, Morten ; Sjöstrand, Mikaela ; Solomon, Scott D ; Verma, Subodh ; Jhund, Pardeep S ; McMurray, John J V. / Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease : an analysis of DAPA-HF. In: European Journal of Heart Failure. 2021 ; Vol. 23, No. 4. pp. 632-643.

Bibtex

@article{83a0b46b40884b9896eb21235a7ff3d4,
title = "Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF",
abstract = "AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under-prescription of beta-blockers. Consequently, additional effective therapies are especially relevant in patients with COPD. The aim of this study was to examine outcomes related to COPD in a post hoc analysis of the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial.METHODS AND RESULTS: We examined whether the effects of dapagliflozin in DAPA-HF were modified by COPD status. The primary outcome was the composite of an episode of worsening HF or cardiovascular death. Overall, 585 (12.3%) of the 4744 patients randomized had a history of COPD. Patients with COPD were more likely to be older men with a history of smoking, worse renal function, and higher baseline N-terminal pro B-type natriuretic peptide, and less likely to be treated with a beta-blocker or mineralocorticoid receptor antagonist. The incidence of the primary outcome was higher in patients with COPD than in those without [18.9 (95% confidence interval 16.0-22.2) vs. 13.0 (12.1-14.0) per 100 person-years; hazard ratio (HR) for COPD vs. no COPD 1.44 (1.21-1.72); P < 0.001]. The effect of dapagliflozin, compared with placebo, on the primary outcome, was consistent in patients with [HR 0.67 (95% confidence interval 0.48-0.93)] and without COPD [0.76 (0.65-0.87); interaction P-value 0.47].CONCLUSIONS: In DAPA-HF, one in eight patients with HFrEF had concomitant COPD. Participants with COPD had a higher risk of the primary outcome. The benefit of dapagliflozin on all pre-specified outcomes was consistent in patients with and without COPD.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03036124.",
keywords = "Chronic obstructive pulmonary disease, Dapagliflozin, Heart failure",
author = "Pooja Dewan and Docherty, {Kieran F} and Olof Bengtsson and {de Boer}, {Rudolf A} and Desai, {Akshay S} and Jaroslaw Drozdz and Hawkins, {Nathaniel M} and Inzucchi, {Silvio E} and Masafumi Kitakaze and Lars K{\o}ber and Kosiborod, {Mikail N} and Langkilde, {Anna Maria} and Daniel Lindholm and Martinez, {Felipe A} and B{\'e}la Merkely and Petrie, {Mark C} and Piotr Ponikowski and Sabatine, {Marc S} and Morten Schou and Mikaela Sj{\"o}strand and Solomon, {Scott D} and Subodh Verma and Jhund, {Pardeep S} and McMurray, {John J V}",
note = "{\textcopyright} 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.",
year = "2021",
month = apr,
doi = "10.1002/ejhf.2083",
language = "English",
volume = "23",
pages = "632--643",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Wiley",
number = "4",

}

RIS

TY - JOUR

T1 - Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease

T2 - an analysis of DAPA-HF

AU - Dewan, Pooja

AU - Docherty, Kieran F

AU - Bengtsson, Olof

AU - de Boer, Rudolf A

AU - Desai, Akshay S

AU - Drozdz, Jaroslaw

AU - Hawkins, Nathaniel M

AU - Inzucchi, Silvio E

AU - Kitakaze, Masafumi

AU - Køber, Lars

AU - Kosiborod, Mikail N

AU - Langkilde, Anna Maria

AU - Lindholm, Daniel

AU - Martinez, Felipe A

AU - Merkely, Béla

AU - Petrie, Mark C

AU - Ponikowski, Piotr

AU - Sabatine, Marc S

AU - Schou, Morten

AU - Sjöstrand, Mikaela

AU - Solomon, Scott D

AU - Verma, Subodh

AU - Jhund, Pardeep S

AU - McMurray, John J V

N1 - © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

PY - 2021/4

Y1 - 2021/4

N2 - AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under-prescription of beta-blockers. Consequently, additional effective therapies are especially relevant in patients with COPD. The aim of this study was to examine outcomes related to COPD in a post hoc analysis of the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial.METHODS AND RESULTS: We examined whether the effects of dapagliflozin in DAPA-HF were modified by COPD status. The primary outcome was the composite of an episode of worsening HF or cardiovascular death. Overall, 585 (12.3%) of the 4744 patients randomized had a history of COPD. Patients with COPD were more likely to be older men with a history of smoking, worse renal function, and higher baseline N-terminal pro B-type natriuretic peptide, and less likely to be treated with a beta-blocker or mineralocorticoid receptor antagonist. The incidence of the primary outcome was higher in patients with COPD than in those without [18.9 (95% confidence interval 16.0-22.2) vs. 13.0 (12.1-14.0) per 100 person-years; hazard ratio (HR) for COPD vs. no COPD 1.44 (1.21-1.72); P < 0.001]. The effect of dapagliflozin, compared with placebo, on the primary outcome, was consistent in patients with [HR 0.67 (95% confidence interval 0.48-0.93)] and without COPD [0.76 (0.65-0.87); interaction P-value 0.47].CONCLUSIONS: In DAPA-HF, one in eight patients with HFrEF had concomitant COPD. Participants with COPD had a higher risk of the primary outcome. The benefit of dapagliflozin on all pre-specified outcomes was consistent in patients with and without COPD.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03036124.

AB - AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under-prescription of beta-blockers. Consequently, additional effective therapies are especially relevant in patients with COPD. The aim of this study was to examine outcomes related to COPD in a post hoc analysis of the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial.METHODS AND RESULTS: We examined whether the effects of dapagliflozin in DAPA-HF were modified by COPD status. The primary outcome was the composite of an episode of worsening HF or cardiovascular death. Overall, 585 (12.3%) of the 4744 patients randomized had a history of COPD. Patients with COPD were more likely to be older men with a history of smoking, worse renal function, and higher baseline N-terminal pro B-type natriuretic peptide, and less likely to be treated with a beta-blocker or mineralocorticoid receptor antagonist. The incidence of the primary outcome was higher in patients with COPD than in those without [18.9 (95% confidence interval 16.0-22.2) vs. 13.0 (12.1-14.0) per 100 person-years; hazard ratio (HR) for COPD vs. no COPD 1.44 (1.21-1.72); P < 0.001]. The effect of dapagliflozin, compared with placebo, on the primary outcome, was consistent in patients with [HR 0.67 (95% confidence interval 0.48-0.93)] and without COPD [0.76 (0.65-0.87); interaction P-value 0.47].CONCLUSIONS: In DAPA-HF, one in eight patients with HFrEF had concomitant COPD. Participants with COPD had a higher risk of the primary outcome. The benefit of dapagliflozin on all pre-specified outcomes was consistent in patients with and without COPD.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03036124.

KW - Chronic obstructive pulmonary disease

KW - Dapagliflozin

KW - Heart failure

U2 - 10.1002/ejhf.2083

DO - 10.1002/ejhf.2083

M3 - Journal article

C2 - 33368858

VL - 23

SP - 632

EP - 643

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -

ID: 62247157